Popovits Kimberly J 4
4 · EXACT SCIENCES CORP · Filed Mar 23, 2026
Research Summary
AI-generated summary of this filing
Exact Sciences (EXAS) Director Kimberly Popovits Sells Shares
What Happened Kimberly J. Popovits, a director of Exact Sciences Corporation, had two dispositions to the issuer on 2026-03-23 totaling 16,381 shares (6,725 + 9,656). Under the merger agreement with Abbott Laboratories, each share of Exact common stock was converted into the right to receive $105.00 in cash, so the shares converted into approximately $1,720,005 in merger consideration (before any applicable tax withholding). This is a corporate cash-out due to the merger, not an open-market sale.
Key Details
- Transaction date: 2026-03-23 (Effective Time of the merger).
- Price per share: $105.00 (merger consideration); total proceeds ≈ $1,720,005 before withholding.
- Shares involved: 6,725 and 9,656 (total 16,381).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes: F1 — shares converted to $105 cash per the Merger Agreement; F2 — restricted/vesting shares deemed fully vested and converted and subject to applicable tax withholding.
- Filing timeliness: Reported on 2026-03-23 (same date as the transaction), indicating a timely Form 4 filing in the provided record.
Context This was a disposition to the issuer as part of the corporate merger (Badger Merger Sub I merged into Exact Sciences, making Exact a wholly owned subsidiary of Abbott). Such transactions reflect the deal consideration rather than an insider decision to trade; restricted shares were treated as vested and converted under the merger terms.
Insider Transaction Report
- Disposition to Issuer
Common Stock
[F1]2026-03-23−6,725→ 9,656 total - Disposition to Issuer
Common Stock
[F2]2026-03-23−9,656→ 0 total
Footnotes (2)
- [F1]On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
- [F2]At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.